Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell
lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for
adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown
favorable results in advanced NSCLC. This study will add bevacizumab to oxaliplatin and
gemcitabine as first line treatment in patients with Stage IIIB and IV NSCLC.